SARTF (Sartorius AG) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SARTF Sartorius AG SARTF
84 GF Score
Price $212.80
GF Value $273.86
Valuation Modestly Undervalued
! 10 Warning Signs
View Full Analysis

What is Sartorius AG Short-term investments?

Short-term investments only applies to insurance companies.

SARTF
84GF Score
Sartorius AG SARTF
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $212.80 is trading 22.3% below its estimated GF Value™ of $273.86. GuruFocus considers Sartorius AG to be Modestly Undervalued.

Key valuation signals for SARTF:

  • Short-term investments:
  • GF Value™: $273.86 vs. price of $212.80 (22.3% below fair value)
  • GF Score™: 84/100 with 10 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
84GF Score

Get the complete analysis for SARTF

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$212.80
Price
$273.86
GF Value